TTR and amyloidosis: In 2018, the world's first siRNA-based drug, Patisiran, was approved for the treatment of hereditary transthyretin-mediated amyloidosis[182], and another siRNA-based drug, Givosiran, was approved in 2020 for adults with acute hepatic porphyria [183].